Trial reportScientific reports2018
KRAS and BRAF mutations in circulating tumour DNA from locally advanced rectal cancer.
Trial report in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 7 syntheses or guidelines pooled it.
- Assessing circulating tumour DNA (ctDNA) as a prognostic biomarker in locally advanced rectal cancer: a systematic review and meta-analysis.International journal of colorectal disease · 2024Pooled it
- Treatment stratification and prognosis assessment using circulating tumor DNA in locally advanced rectal cancer: A systematic review and meta-analysis.Cancer medicine · 2023Pooled it
- Circulating tumour DNA as biomarker for rectal cancer: A systematic review and meta-analyses.Frontiers in oncology · 2023Pooled it
- Reliability of BRAF mutation detection using plasma sample: A systematic review and meta-analysisMedicine · 2021Pooled it
- Pooled it
- Cell-free DNA and preoperative chemoradiotherapy for rectal cancer: a systematic review.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2019Pooled it
- Circulating Cell-Free DNA and Colorectal Cancer: A Systematic Review.International journal of molecular sciences · 2018Pooled it
- Site-Specific Mutations on KRAS, NRAS, and BRAF Corelate With the Frequency of ctDNA in Colorectal Cancer.Cancer reports (Hoboken, N.J.) · 2025Article
- Utilizing intratumoral and peritumoral ultrasound radiomics for predicting KRAS gene mutation status in rectal cancer patients.Journal of applied clinical medical physics · 2025Article
- Comparison of Intratumoral and Peritumoral Deep Learning, Radiomics, and Fusion Models for Predicting KRAS Gene Mutations in Rectal Cancer Based on Endorectal Ultrasound Imaging.Annals of surgical oncology · 2025Article
- Using tumor habitat-derived radiomic analysis during pretreatmentCancer imaging : the official publication of the International Cancer Imaging Society · 2024Article
- Circulating tumour DNA in colorectal cancer management.The British journal of surgery · 2023Article
- Analysis of Circulating Tumor DNA in Synchronous Metastatic Colorectal Cancer at Diagnosis Predicts Overall Patient Survival.International journal of molecular sciences · 2023Article
- Review
- Circulating tumour DNA in the evolving treatment landscape of locally advanced rectal cancer: where does it fit in?Therapeutic advances in medical oncology · 2023Review
- Relationship between perioperative oncological evaluation and recurrence using circulating tumor DNA with KRAS mutation in patients with colorectal cancer.Cancer medicine · 2022Article
- The Prognostic Importance of ctDNA in Rectal Cancer: A Critical Reappraisal.Cancers · 2022 · on this mapReview
- Liquid biopsy approaches and immunotherapy in colorectal cancer for precision medicine: Are we there yet?Frontiers in oncology · 2022Review
- Tumor irradiation may facilitate the detection of tumor-specific mutations in plasma.World journal of clinical oncology · 2021Article
- Applications of liquid biopsy in the Pharmacological Audit Trail for anticancer drug development.Nature reviews. Clinical oncology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
Abstract
There are limited data on circulating, cell-free, tumour (ct)DNA analysis in locally advanced rectal cancer (LARC). Digital droplet (dd)PCR was used to investigate KRAS/BRAF mutations in ctDNA from baseline blood samples of 97 LARC patients who were treated with CAPOX followed by chemoradiotherapy, surgery and adjuvant CAPOX ± cetuximab in a randomised phase II trial. KRAS mutation in G12D, G12V or G13D was detected in the ctDNA of 43% and 35% of patients with tumours that were mutant and wild-type for these hotspot mutations, respectively, according to standard PCR-based analyses on tissue. The detection rate in the ctDNA of 10 patients with less common mutations was 50%. In 26 cases ctDNA analysis revealed KRAS mutations that were not previously found in tissue. Twenty-two of these (84.6%) were detected following repeat tissue testing by ddPCR. Overall, the ctDNA detection rate in the KRAS mutant population was 66%. Detection of KRAS mutation in ctDNA failed to predict prognosis or refine patient selection for cetuximab. While this study confirms the feasibility of ctDNA analysis in LARC and the high sensitivity of ddPCR, larger series are needed to better address the role of ctDNA as a prognostic or predictive tool in this setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.